BCC’s goal in conducting this study is to provide an overview of the current and potential aspects of the global market for advanced drug delivery systems and its future direction, with an emphasis on newer techniques and products. The report determines the market size and market leaders, provides a market overview, and examines factors affecting the markets for drug delivery systems, including the use of these products in therapeutic markets.

1. Advanced Drug Delivery Systems: Technologies and Global Markets
STUDY OBJECTIVES
BCC’s goal in conducting this study is to provide an overview of the current and potential
aspects of the global market for advanced drug delivery systems and its future direction,
with an emphasis on newer techniques and products. The report determines the market size
and market leaders, provides a market overview, and examines factors affecting the
markets for drug delivery systems, including the use of these products in therapeutic
markets.
An overview of types of drug delivery systems is also examined along with sales figures
over the 5 year period from 2009 to 2014. This study provides an overview of the drug
delivery market, which BCC projects will grow at a compound annual growth rate (CAGR) of
7.2% over the forecast period 2009 through 2014.
The study presents market size and future trends, profiles market leaders, and analyzes
factors affecting drug delivery markets and important products. The report also examines
future trends in drug delivery technology, the basic principles underlying different systems,
and their applications. Companies manufacturing and selling the drug delivery products are
also profiled. Revenues have been broken down by the type of drug delivery systems and
by different regions.
Our key objective is to present a comprehensive analysis of the current market and the
future direction of the advanced drug delivery systems.
REASONS FOR DOING THIS STUDY
The drug delivery market is changing drastically due to the introduction of new techniques
and routes of delivery. R&D spending, along with increasing competition, patent expiries,
new technologies, an international marketplace, and a changing customer base, is creating
a new kind of market for drug delivery systems. This study looks at almost all the systems
affected by these factors.
This is a very complex market, where many technologies are combined together to produce
a better delivery system, thus creating niche markets with very specialized applications.
The use of liposomes, polymers, etc. in the sustained-release oral/injectable drug delivery
market is a good example. Prodrugs, PEGylation, nanoparticles, and liposomes are
significant new markets.
Acquisition strategies and collaborations by companies are also covered in this report, for
example, the acquisition of the Pulmonary Division of Nektar Therapeutics by Novartis. This
study also discusses the strength and weaknesses of drug development market in light of
the new technologies, growing competition, and changing customer needs.
INTENDED AUDIENCE
The report consolidates much of the information on new products and new technologies in
the drug delivery industry. The study contributes to understanding market growth and
decline in drug delivery market from the point of view of the manufacturer and user. This
study will be of interest to manufacturers and end-users in the pharmaceutical and
biotechnology industries, and to companies involved in R&D for drug delivery systems and
new drugs.

2. SCOPE OF THE STUDY
This study encompasses the major types of drug delivery systems used in the health
industry. BCC analyzes each technology and looks at the manufacturers, their new
products, sales estimates, market projections, and some market share information. BCC
analyzes the industry on a worldwide basis. Patents for drug delivery technologies are also
studied by year, country, and assignee. The Food and Drug Administration (FDA) approvals
for the past 5 years have been covered. New developments in this field have been
examined in detail, including those that comprise a part of individual company profiles.
METHODOLOGY
Both primary and secondary research methods were used in this report. A comprehensive
search of the literature was conducted. The literature included technical newsletters and
journals as well as many other sources. The data were collected through interviews and
correspondence with various pharmaceutical/ biotechnical experts. Projections were based
on estimates such as the current number of end users, potential end users, likely unit
prices, rates of consumption, and market trends.
INFORMATION SOURCES
BCC surveyed many companies to obtain data for this study. We gathered the data from
these industries, spoke with officials, and consulted newsletters, company literature,
product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustive
investigations of databases by key terminology were done. In addition, we compiled data
from current financial and trade information and government sources.
ABOUT THE AUTHOR
Shalini Shahani Dewan holds a Masters Degree in pharmaceutical chemistry. Among the
research topics she has covered are studies on compounds of potential pharmaceutical
interest from ibuprofen and 2-naphthyl acetic acid. Shahani was awarded a gold medal by
the prime minister of India for her work and has worked with top companies in India and in
the U.S. Some of her other reports with BCC are: Reagents of Chromatography;
Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems; Orthopedic Drugs,
Implants and Devices; Imaging Reagents; Contract Manufacturing, Research and
Packaging; The Dynamic Media, Sera and Reagent Market in Biotechnology;Opportunities in
Chiral Technology;Behavioral and Emotional Disorders in Children and Adolescents; and
Pharmaceutical Regulatory Industry; and many more.
Table Of Contents
Chapter- 1: INTRODUCTION – Complimentary
STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
INTENDED AUDIENCE
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ABOUT THE AUTHOR

3. RELATED BCC REPORTS
BCC ONLINE SERVICES
DISCLAIMER
Chapter- 2: SUMMARY
Table 0 : GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, THROUGH 2014
Figure 0 : GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, 2007-2014
Chapter- 3: OVERVIEW
DEFINITIONS
CLASSIFICATION OF DRUG DELIVERY ACCORDING TO ROUTE OF ADMINISTRATION
CLASSIFICATION OF DRUG DELIVERY BASED ON TECHNOLOGY
Chapter- 4: REGULATORY ISSUES
Table 21 : FDA-APPROVED DRUGS OF VARIOUS DOSAGE FORMS
Table 22 : NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH
YEAR, 2005- FEB. 2009
Figure 1 : NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH
YEAR, 2005 TO FEB. 2009
Table 23 : APPROVED DRUGS OF VARIOUS DOSAGE FORMS, THROUGH OTHER
AGENCIES
Table 24 : RECALLS/ SAFETY ALERTS FOR DRUG DELIVERY SYSTEMS
Chapter- 5: CLASSIFICATION OF DRUG PRODUCTS BASED ON DRUG DELIVERY
TYPE
SUSTAINED-RELEASE ORAL DOSAGE FORMS
SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS
SUSTAINED-RELEASE TOPICAL DOSAGE FORMS
PRODRUGS
IMPLANTS AND IUDS
TRANSDERMAL DRUG DELIVERY SYSTEMS
LIPOSOMES
NANOPARTICLES
POLYMERS
MONOCLONAL ANTIBODIES
PEGYNOLOGY
BUCCAL DRUG DELIVERY SYSTEMS
RECTAL DRUG DELIVERY SYSTEMS
VAGINAL DRUG DELIVERY SYSTEMS
OCULAR DRUG DELIVERY SYSTEMS
INHALATION SYSTEMS
Table 40 : MAJOR SUPPLIERS AND MANUFACTURERS OF INHALTION SYSTEMS
Chapter- 6: INDUSTRY STRUCTURE
SUSTAINED-RELEASE DOSAGE FORMS
PRODRUGS
IMPLANTS AND IUDS
TRANSDERMAL DRUG DELIVERY SYSTEMS
TARGETED DRUG DELIVERY SYSTEMS

4. TRANSMUCOSAL DRUG DELIVERY SYSTEMS
Chapter- 7: DEMAND AND USE
OVERALL DRUG DELIVERY MARKET
FACTORS AFFECTING THE DRUG DELIVERY TECHNOLOGY MARKET
Chapter- 8: MARKET ANALYSIS
SUSTAINED-RELEASE ORAL DOSAGE FORMS
SUSTAINED-RELEASE INJECTABLE DOSGAE FORM
SUSTAINED-RELEASE TOPICAL DOSAGE FORMS
PRODRUGS
IMPLANTS AND IUDS
TRANSDERMAL DRUG DELIVERY
LIPOSOMES DRUG DELIVERY
NANOPARTICLES
POLYMERS
PEGYLATED DRUG DELIVERY
MONOCLONAL ANTIBODIES
BUCCAL DRUG DELIVERY
RECTAL DRUG DELIVERY
OCULAR DRUG DELIVERY
VAGINAL DRUG DELIVERY
INHALATION DRUG DELIVERY
Chapter- 9: NEW DEVELOPMENTS
Table 77 : DEVELOPMENTS IN SUSTAINED-RELEASE ORAL DOSAGE FORMS
Table 78 : DEVELOPMENTS IN SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS
Table 79 : DEVELOPMENTS IN SUSTAINED-RELEASE TOPICAL DOSAGE FORMS
Table 80 : DEVELOPMENTS IN PRODRUGS
Table 81 : DEVELOPMENTS IN IMPLANTS AND IUDS
Table 82 : DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS
Table 83 : DEVELOPMENTS IN LIPOSOMAL DELIVERY
Table 84 : DEVELOPMENTS IN PEGYLATED DRUG DELIVERY
Table 85 : DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERY
Table 86 : DEVELOPMENTS IN MONOCLONAL ANTIBODIES
Table 87 : DEVELOPMENTS IN BUCCAL DRUG DELIVERY
Table 88 : DEVELOPMENTS IN VAGINAL DRUG DELIVERY
Table 89 : DEVELOPMENTS IN RECTAL DRUG DELIVERY
Chapter- 10: MARKET BY THERAPEUTIC AREAS
MARKET SIZE
MARKET SHARE
CARDIOVASCULAR DISEASES
ONCOLOGY
GASTROINTESTINAL
UROLOGY
DIABETES
CENTRAL NERVOUS SYSTEM DISORDER
RESPIRATORY DRUG DELIVERY SYSTEMS

5. INFLAMMATORY DISEASES AND ALLERGY
OPHTHALMOLOGY
VIRAL AND BACTERIAL DISEASES
HORMONE REPLACEMENT THERAPY (HRT) AND GYNECOLOGY
OTHERS
Chapter- 11: PATENT ANALYSIS
PATENTS BY YEAR
PATENTS BY TYPE
PATENTS BY COUNTRY
PATENTS BY COMPANY
PATENTS BY ASSIGNEE
Table 109 : NUMBER OF PATENTS BY ASSIGNEE, 2005-2009
Figure 55 : NUMBER OF PATENTS BY ASSIGNEE, 2005-2009
Chapter- 12: COMPANY PROFILES
ABBOTT LABORATORIES
ABRAXIS BIOSCIENCE, INC.
AKELA PHARMA
AKORN, INC.
ALCON, INC.
ALEXION PHARMACEUTICALS
ALKERMES, INC.
ALLERGAN
ALPHARX
AMGEN
ANTIGENICS
A P PHARMA
ASTELLAS PHARMA
ASTRAZENECA
ATON PHARMA
BARR PHARMACEUTICALS, INC.
BAXTER
BAYER HEALTHCARE
BIOGEN IDEC
BIOSANTE PHARMACEUTICALS, INC.
BIOVAIL
BOEHRINGER INGELHEIM
BRISTOL MYERS SQUIBB
CENTOCOR
CEPHALON INC.
COLUMBIA LABS
DIATOS SA
EISAI CO.
ELAN
ENZON
EURAND N.V.
GENENTECH
GENEREX BIOTECH
GENZYME

6. GILEAD SCIENCES, INC.
GLAXOSMITHKLINE PLC
IMCLONE SYSTEMS
JOHNSON AND JOHNSON
KING PHARMACEUTICALS
K.V. PHARMACEUTICAL CO.
LAVIPHARM CORPORATION
3M COMPANY
MERCK & CO.
MYLAN LABORATORIES, INC.
NEKTAR THERAPEUTICS
NOVEN PHARMACEUTICALS, INC.
NOVARTIS AG
NOVAVAX, INC.
NYCOMED US, INC.
OSI PHARMACEUTICALS, INC.
PAR PHARMACEUTICAL COMPANIES, INC.
PDL BIOPHARMA, INC.
PFIZER INC.
QLT, INC.
ROCHE
SANOFI-AVENTIS
SCHERING-PLOUGH
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
WATSON PHARMACEUTICALS, INC.
WYETH, INC.
ABBREVIATIONS
List of Tables
Summary Table : GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, THROUGH 2014
Table 1 : GASEOUS DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES
Table 2 : LIQUID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES
Table 3 : SEMISOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES
Table 4 : SOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES
Table 5 : TOPICAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES
Table 6 : ORAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES
Table 7 : INJECTABLE OR PARENTERAL DRUG DELIVERY, ADVANTAGES AND
DISADVANTAGES
Table 8 : RECTAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES
Table 9 : NASAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES
Table 10 : VAGINAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES
Table 11 : OCULAR DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES
Table 12 : PULMONARY DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES
Table 13 : SUSTAINED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES
Table 14 : DELAYED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES
Table 15 : PRODRUGS, ADVANTAGES AND DISADVANTAGES
Table 16 : IMPLANTS AND IUDS, ADVANTAGES AND DISADVANTAGES
Table 17 : LIPOSOMES, ADVANTAGES AND DISADVANTAGES
Table 18 : POLYMERS, ADVANTAGES AND DISADVANTAGES

7. Table 19 : MONOCLONAL ANTIBODIES, ADVANTAGES AND DISADVANTAGES
Table 20 : PEGYLATION, ADVANTAGES AND DISADVANTAGES
Table 21 : FDA-APPROVED DRUGS OF VARIOUS DOSAGE FORMS
Table 22 : NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR,
2005- FEB. 2009
Table 23 : APPROVED DRUGS OF VARIOUS DOSAGE FORMS, THROUGH OTHER AGENCIES
Table 24 : RECALLS/ SAFETY ALERTS FOR DRUG DELIVERY SYSTEMS
Table 25 : MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE ORAL
DOSAGE FORMS
Table 26 : MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE INJECTABLE
DOSAGE FORMS
Table 27 : MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE TOPICAL
DOSAGE FORMS
Table 28 : MAJOR SUPPLIERS AND MANUFACTURERS OF PRODRUGS
Table 29 : MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDS
Table 30 : MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERY
SYSTEMS
Table 31 : MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMES
Table 32 : MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLES
Table 33 : MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERS
Table 34 : MAJOR SUPPLIERS AND MANUFACTURERS OF MONOCLONAL ANTIBODIES
Table 35 : MAJOR SUPPLIERS AND MANUFACTURERS OF PEGNOLOGY
Table 36 : MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL DRUG DELIVERY SYSTEMS
Table 37 : MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL DRUG DELIVERY SYSTEMS
Table 38 : MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL DRUG DELIVERY
SYSTEMS
Table 39 : MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR DRUG DELIVERY
SYSTEMS
Table 40 : MAJOR SUPPLIERS AND MANUFACTURERS OF INHALTION SYSTEMS
Table 41 : SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE ORAL
DOSAGE FORMS, 2008
Table 42 : SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE
INJECTABLE DOSAGE FORMS, 2008
Table 43 : SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE TOPICAL
DOSAGE FORMS, 2008
Table 44 : SHARES OF MANUFACTURERS/SUPPLIERS FOR PRODRUGS, 2008`
Table 45 : SHARES OF MANUFACTURERS FOR IMPLANTS AND IUDS, 2008
Table 46 : SHARES OF MANUFACTURERS/SUPPLIERS FOR TRANSDERMAL DRUG DELIVERY
SYSTEMS, 2008
Table 47 : SHARES OF MANUFACTURERS/SUPPLIERS FOR LIPOSOMES, 2008
Table 48 : SHARES OF MANUFACTURERS/SUPPLIERS FOR NANOPARTICLES, 2008
Table 49 : SHARES OF MANUFACTURERS/SUPPLIERS FOR POLYMERS, 2008
Table 50 : SHARES OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2008
Table 51 : SHARES OF MANUFACTURERS/SUPPLIERS FOR PEGNOLOGY, 2008
Table 52 : SHARES OF MANUFACTURERS/SUPPLIERS FOR BUCCAL DRUG DELIVERY
SYSTEMS, 2008
Table 53 : SHARES OF MANUFACTURERS/SUPPLIERS FOR RECTAL DRUG DELIVERY
SYSTEMS, 2008
Table 54 : SHARES OF MANUFACTURERS/SUPPLIERS FOR VAGINAL DRUG DELIVERY

8. SYSTEMS, 2008
Table 55 : SHARES OF MANUFACTURERS/SUPPLIERS FOR OCULAR DRUG DELIVERY
SYSTEMS, 2008
Table 56 : SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008
Table 57 : DRUGS WHICH LOST THEIR PATENTS IN 2008
Table 58 : DRUGS WHICH WILL LOSE THEIR PATENTS IN 2009
Table 59 : GLOBAL SALES OF DRUG DELIVERY PRODUCTS, THROUGH 2014
Table 60 : MARKET SHARE OF DRUG DELIVERY PRODUCTS, 2008
Table 61 : GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, THROUGH 2014
Table 62 : GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS,
THROUGH 2014
Table 63 : GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, THROUGH
2014
Table 64 : TOTAL GLOBAL SALES OF PRODRUGS, THROUGH 2014
Table 65 : GLOBAL SALES OF IMPLANTS AND IUDS, THROUGH 2014
Table 66 : GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2014
Table 67 : GLOBAL SALES OF LIPOSOMES, THROUGH 2014
Table 68 : GLOBAL SALES OF NANOPARTICLES, THROUGH 2014
Table 69 : GLOBAL SALES OF POLYMERS, THROUGH 2014
Table 70 : GLOBAL SALES OF PEGYLATED DRUG DELIVERY, THROUGH 2014
Table 71 : GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2014
Table 72 : GLOBAL SALES OF BUCCAL DRUG DELIVERY, THOUGH 2014
Table 73 : GLOBAL SALES OF RECTAL DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)
Table 74 : GLOBAL SALES OF OCULAR DRUG DELIVERY, THROUGH 2014
Table 75 : GLOBAL SALES OF VAGINAL DRUG DELIVERY, THROUGH 2014
Table 76 : GLOBAL SALES OF INHALATION DRUG DELIVERY, THROUGH 2014
Table 77 : DEVELOPMENTS IN SUSTAINED-RELEASE ORAL DOSAGE FORMS
Table 78 : DEVELOPMENTS IN SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS
Table 79 : DEVELOPMENTS IN SUSTAINED-RELEASE TOPICAL DOSAGE FORMS
Table 80 : DEVELOPMENTS IN PRODRUGS
Table 81 : DEVELOPMENTS IN IMPLANTS AND IUDS
Table 82 : DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS
Table 83 : DEVELOPMENTS IN LIPOSOMAL DELIVERY
Table 84 : DEVELOPMENTS IN PEGYLATED DRUG DELIVERY
Table 85 : DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERY
Table 86 : DEVELOPMENTS IN MONOCLONAL ANTIBODIES
Table 87 : DEVELOPMENTS IN BUCCAL DRUG DELIVERY
Table 88 : DEVELOPMENTS IN VAGINAL DRUG DELIVERY
Table 89 : DEVELOPMENTS IN RECTAL DRUG DELIVERY
Table 90 : DEVELOPMENTS IN INHALATION DRUG DELIVERY
Table 91 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN EACH THERAPEUTIC AREA,
THROUGH 2014
Table 92 : SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008
Table 93 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES,
THROUGH 2004
Table 94 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, THROUGH 2014
Table 95 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL
DISORDERS, THROUGH 2014
Table 96 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, THROUGH 2014

9. Table 97 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, THROUGH
2014
Table 98 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTERAL NERVOUS SYSTEM
MARKET, THROUGH 2014
Table 99 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RESPIRATORY DISEASES,
THROUGH 2014
Table 100 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND
ALLERGY, 2007-2014
Table 101 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH
2014
Table 102 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL
DISEASES, THROUGH 2014
Table 103 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT
THERAPY AND GYNECOLOGY, THROUGH 2014
Table 104 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS
AND TECHNOLOGIES, THROUGH 2014
Table 105 : TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2009
Table 106 : NUMBER OF PATENTS BY TYPE, 2005-2009
Table 107 : TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009
Table 108 : NUMBER OF PATENTS BY COMPANY, 2005-2009
Table 109 : NUMBER OF PATENTS BY ASSIGNEE, 2005-2009
List of Figures
Summary Figure : GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, 2007-2014
Figure 1 : NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR,
2005 TO FEB. 2009
Figure 2 : SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE ORAL
DOSAGE FORMS, 2008
Figure 3 : SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE INJECTABLE
DOSAGE FORMS, 2008
Figure 4 : SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE TOPICAL
DOSAGE FORMS, 2008
Figure 5 : SHARES OF MANUFACTURERS/SUPPLIERS OF PRODRUGS, 2008
Figure 6 : SHARES OF MANUFACTURERS OF IMPLANTS AND IUDS, 2008
Figure 7 : SHARES OF MANUFACTURERS/SUPPLIERS OF TRANSDERMAL DRUG DELIVERY
SYSTEMS, 2008
Figure 8 : SHARES OF MANUFACTURERS/SUPPLIERS OF LIPOSOMES, 2008
Figure 9 : SHARES OF MANUFACTURERS/SUPPLIERS OF NANOPARTICLES, 2008
Figure 10 : SHARES OF MANUFACTURERS/SUPPLIERS OF POLYMERS, 2008
Figure 11 : Shares of MANUFACTURERS/suppliers of monoclonal antibodies, 2008
Figure 12 : SHARES OF MANUFACTURERS/SUPPLIERS OF PEGNOLOGY, 2008
Figure 13 : SHARES OF MANUFACTURERS/ SUPPLIERS OF BUCCAL DRUG DELIVERY
SYSTEMS, 2008
Figure 14 : SHARES OF MANUFACTURERS/ SUPPLIERS OF RECTAL DRUG DELIVERY
SYSTEMS, 2008
Figure 15 : SHARES OF MANUFACTURERS/ SUPPLIERS OF VAGINAL DRUG DELIVERY
SYSTEMS, 2008
Figure 16 : SHARES OF MANUFACTURERS/SUPPLIERS OF OCULAR DRUG DELIVERY
SYSTEMS, 2008

10. Figure 17 : SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008
Figure 18 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS, 2007-2014
Figure 19 : MARKET SHARE OF DRUG DELIVERY SYSTEM, 2008
Figure 20 : TOTAL GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2007-
2014
Figure 21 : TOTAL GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS,
2007-2014
Figure 22 : TOTAL GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS,
2007-2014
Figure 23 : GLOBAL SALES OF PRODRUGS, 2007-2014
Figure 24 : TOTAL GLOBAL SALES OF IMPLANTS AND IUDS, 2007-2014
Figure 25 : TOTAL GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2007-
2014
Figure 26 : TOTAL GLOBAL SALES OF LIPOSOMES, 2007-2014
Figure 27 : GLOBAL SALES OF NANOPARTICLES, 2007-2014
Figure 28 : GLOBAL SALES OF POLYMERS, 2007-2014
Figure 29 : TOTAL GLOBAL SALES OF PEGYLATED DRUG DELIVERY, 2007-2014
Figure 30 : TOTAL GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2007-2014
Figure 31 : TOTAL GLOBAL SALES OF BUCCAL DRUG DELIVERY, 2007-2014
Figure 32 : TOTAL GLOBAL SALES OF RECTAL DRUG DELIVERY, 2007-2014
Figure 33 : TOTAL GLOBAL SALES OF OCULAR DRUG DELIVERY, 2007-2014
Figure 34 : TOTAL GLOBAL SALES OF VAGINAL DRUG DELIVERY, 2007-2014
Figure 35 : TOTAL GLOBAL SALES OF INHALATION DRUG DELIVERY, 2007-2014
Figure 36 : GLOBAL SALES OF DRUGS TO TREAT LIVER DISEASES, 2007-014
Figure 37 : SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008
Figure 38 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES,
2007-2014
Figure 39 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, 2007-2014
Figure 40 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL
DISORDERS, 2007-2014
Figure 41 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, 2007-2014
Figure 42 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, 2007-2014
Figure 43 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTRAL NERVOUS SYSTEM
MARKET, 2007-2014
Figure 44 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RISPIRATORY DISEASES,
2007-2014
Figure 45 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND ALLERGY
DISEASES, 2007-2014
Figure 46 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, 2007-2014
Figure 47 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL
DISEASES, 2007-2014
Figure 48 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT
THERAPY AND GYNECOLOGY, 2007-2014
Figure 49 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS
AND TECHNOLOGIES, 2007-2014
Figure 50 : NUMBER OF PATENTS, 2005-2009
Figure 51 : NUMBER OF PATENTS BY TYPE, 2005-2009
Figure 52 : TOTAL NUMBER OF PATENTS, SHARE BY TYPE, 2005-2009
Figure 53 : TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009

11. Figure 54 : NUMBER OF PATENTS BY COMPANY, 2005-2009
Figure 55 : NUMBER OF PATENTS BY ASSIGNEE, 2005-2009
Latest Market Research Reports:
 Global Market for Catalyst Regeneration
 Markets for Advanced Wound Care Technologies
 Wireless Sensors: Technologies and Global Markets
 Remote Sensing Technologies and Global Markets
 Portable Battery Powered Products: Global Markets
 Sample Preparation in Genomics, Proteomics, and Epigenomics: Global Markets
 Embedded Systems: Technologies and Markets
About Us:
ReportsnReports is an online library of over 75,000 market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit Our Market Research Reports Blog